drugset / Trial / NCT01844310

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

NCT01844310

Unknown 300 enrolled Peking Union Medical College
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the safety and efficacy of RAL-based regimen in treatment-experienced patients with resistant HIV infection

Timeline

Start
2013-05
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lamivudine Other / unclassified
Comparator Raltegravir Other / unclassified
Comparator KELETRA Unknown
Comparator TDF Unknown

Indications